Overview

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To investigate the safety of polyethylene glycolated interleukin-2 (PEG IL-2) given subcutaneously in conjunction with antiviral treatment and to explore the effects of treatment on surrogate markers of efficacy and incidence of opportunistic infection and other clinical markers of HIV disease.

Phase:

N/A

Details

Lead Sponsor:

Chiron Corporation

Treatments:

Didanosine
Interleukin-2
Zidovudine